Clinical Scorecard: Use of Oral Anticoagulants in Atrial Fibrillation Patients with Advanced Chronic Kidney Disease Not Undergoing Dialysis

At a Glance

Key Highlights

• 12% to 18% of individuals with CKD are estimated to have AF.
• Warfarin remains widely prescribed despite the growing use of DOACs.
• Apixaban is FDA-approved for stroke prevention in AF with severe kidney impairment.
• Existing guidelines vary on OAC initiation and dosing in advanced CKD.
• Observational studies show inconsistent outcomes for apixaban versus warfarin.

Guideline-Based Recommendations

Diagnosis

• Diagnosis of AF requires at least one inpatient or two outpatient diagnoses.

Management

• Consider apixaban or warfarin for patients with AF and advanced CKD.

Monitoring & Follow-up

• Monitor for major bleeding and ischemic stroke hospitalizations.

Risks

• Increased risk of bleeding with OACs in patients with advanced CKD.

Patient & Prescribing Data

Patients aged 65 years or older with stage 4 or 5 CKD and AF.

Apixaban may have less bleeding risk compared to warfarin in advanced CKD.

Clinical Best Practices

• Use validated algorithms for CKD identification.
• Evaluate CHA2DS2-VASc scores for OAC initiation.
• Ensure continuous medical and pharmacy coverage for patients.

Related Resources & Content

• Study on CKD and AF prevalence
• FDA approval of apixaban
• Guidelines on OAC management in CKD